Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Accused Surgeon Found Not Guilty by District Court
September 1, 2008
- Korosho to Demand Budget to Increase PMDA Staff Responsible for Safety Measures by 100
September 1, 2008
- JCR to Request Application for Higher Doses of MTX Based on Public Knowledge
September 1, 2008
- Yamato HD to Introduce New Direct Delivery System for Generics
September 1, 2008
- Doctors' Awareness Needs to Be Renovated to Popularize Biologics for RA
September 1, 2008
- Statistics／Drug Sales Up 0.7% in June: Crecon R&C
September 1, 2008
- No Evidence for Giving Priority to Iressa: CDFS
September 1, 2008
- Tokai Univ. to Settle Prices of Individual Drugs within Sept.
September 1, 2008
- MEDICAL DEVICE NEWS IN BRIEF
September 1, 2008
- Oracle to Enhance Software Development for Pharma Industry
September 1, 2008
- Revisions of Package Inserts Ordered for Devices Used for Artificial Ventilation
September 1, 2008
- PI Forum Members Should Use Their Franchise Technologies to Develop New Drugs
September 1, 2008
- SELF-MEDICATION NEWS IN BRIEF
September 1, 2008
- Yakult to Develop Celsion's Thermally Sensitive Doxorubicin in Japan
September 1, 2008
- OPINION
September 1, 2008
- Nippon Kayaku to Support Growth by Proprietary Micellar Technology
September 1, 2008
- R&D NEWS IN BRIEF
September 1, 2008
- Takeda to Become One of the Top-Three Oncology Companies: President Hasegawa
September 1, 2008
- Kyorin Obtains Encouraging PIIa Results with KRP-104
September 1, 2008
- Nisshin Seifun Withdraws from Ethical Drug Business by Selling Joint Venture to Kyorin
September 1, 2008
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…